Efficacy of Pethidine, Ketorolac And Xylocaine Gel As Analgesics For Pain Control In Shockwave Lithotripsy
- Conditions
- UrolithiasisAnalgesia
- Interventions
- Registration Number
- NCT03032458
- Lead Sponsor
- Mansoura University
- Brief Summary
A randomised prospective trial comparing the efficacy of pethidine, Ketorolac, and Xylocaine gel as analgesics for pain control in shockwave lithotripsy.
- Detailed Description
Pain perception during shockwave lithotripsy (SWL) is affected by patient-related factors like age, gender, and body habitus moreover, young female patients, anxious and depressed patients or thin patients experience more pain during SWL.
Several physical variables influencing treatment-related pain have been identified: the type of the shockwave source, size, and site of stone burden, peak pressure of the shockwaves, diameter of the focal zone, and size of the aperture of the shockwave source reflecting the area of shockwave entry at the skin.
Pain relief during SWL is vital, not only to maintain patient comfort and satisfaction, but also to facilitate stone imaging and targeting by reducing patients' movements during successive shock wave impacts. Reduced patient movement enables increase fragmentation efficiency and reduce the risk of procedure-related morbidity. So, a relaxed, cooperative patient during treatment is paramount in maintaining stone targeting for optimal fragmentation.
Across 21 centers in the United Kingdom (UK), 17 distinct analgesia regimens were reported in SWL analgesia practice.
In 2016 European Association of Urology (EUA) guidelines for SWL Pain control stated that pain control during SWL is necessary to limit pain induced movements and excessive respiratory excursions, However no recommendation for proper analgesia in contrast to clear recommendation for Pain relief in patients with an acute stone episode.
The investigators will try in this trial to identify the best efficacious type of analgesia for patient during SWL in this study.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 165
- Patients with renal and upper ureteral stones amenable to SWL.
- Allergy to pethidine.
- Allergy to Ketorolac.
- Allergy to Xylocaine gel.
- American Society of Anesthesiologists score ≥ 3 (ASA III or more).
- Pregnancy.
- Patients with a pacemaker.
- Bleeding diatheses.
- Uncontrolled urinary tract infection (UTI).
- Severe obesity which prevent targeting of the stone.
- Body Mass IndexBMI (40 or more)
- Arterial aneurysm in the vicinity of the stone.
- Anatomical obstruction distal to the stone.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Xylocaine Gel Xylocaine Gel Xylocaine gel (lidocaine 2%, AstraZeneca Pharmaceutical Company - Egypt) Pethidine Pethidine Pethidine 25 mg IV bolus (Pethidine hydrochloride 50mg ampule, Roche Pharmaceutical Company - Egypt) Ketorolac Ketorolac Ketolac 30 mg (ketorolac, Amriya Pharmaceutical Industries - Egypt)
- Primary Outcome Measures
Name Time Method Pain control __ Outcome Measure by "pain assessment scales of The National Initiative on Pain Control™ (NIPC™)" 10 months
- Secondary Outcome Measures
Name Time Method Compare stone free rate __ Outcome Measure by "ultrasound and plain x-ray" 1 week after session. If no residual stone, NCCT scan. 1 year Effect of anxiety on success of SWL __ Outcome Measure by "The Patient Health Questionnaire (PHQ-9)" 10 months Effect of anxiety on success of SWL __ Outcome Measure by "Generalized Anxiety Disorder 7-item " 10 months
Trial Locations
- Locations (1)
Urology and Nephrology Center
🇪🇬Mansourah, Aldakahlia, Egypt